Table 1.
Demographic and clinical characteristics in patients with non-viremic and viremic patients
| Non-viremia | Viremia | P-value | |
|---|---|---|---|
| No. of patients | 896 | 102 | |
| Recipient gender (male) | 526 (58.7%) | 78 (76.5%) | <0.001 |
| Recipient age (years) | 49 ± 17 | 48 ± 18 | 0.61 |
| Etiology of ESRD | |||
| Glomerulonephritis | 179 (20.0%) | 18 (17.7%) | 0.87 |
| Hypertension | 119 (13.3%) | 15 (14.7%) | |
| Diabetes | 272 (30.4%) | 29 (28.4%) | |
| Others | 326 (36.3%) | 40 (39.2%) | |
| First graft | 713 (79.6%) | 76 (74.5%) | 0.23 |
| Cadaveric donor | 565 (63.1%) | 66 (64.7%) | 0.74 |
| Donor age (years) | 40 ± 16 | 38 ± 15 | 0.24 |
| Cold ischemic time (min) | 951 ± 755 | 1034 ± 859 | 0.30 |
| HLA mismatch HLA-A | 1.15 ± 0.76 | 1.29 ± 0.65 | 0.068 |
| HLA-B | 1.37 ± 0.71 | 1.54 ± 0.59 | 0.020 |
| HLA-DR | 1.16 ± 0.72 | 1.25 ± 0.67 | 0.25 |
| A + B + DR | 3.68 ± 1.74 | 4.09 ± 1.44 | 0.023 |
| PRA > 20% | 159 (17.8%) | 18 (17.7%) | 0.98 |
| Induction therapy | |||
| Alemtuzumab | 850 (94.9%) | 96 (94.1%) | 0.68 |
| Thymoglobulin | 21 (2.3%) | 2 (2.0%) | |
| Dacrizmab | 12 (1.4%) | 1 (1.0%) | |
| Basiliximab | 2 (0.2%) | 0 (0.0%) | |
| No antibody induction | 11 (1.2%) | 3 (2.9%) | |
| Maintenance immunosuppression | |||
| Tac monotherapy | 651 (72.7%) | 64 (62.7%) | 0.003 |
| Tac + MMF | 156 (17.4%) | 21 (20.6%) | |
| Tac + PSL | 50 (5.6%) | 12 (11.8%) | |
| Others | 39 (4.3%) | 5 (3.9%) | |
| Acute rejection episode | 236 (26.3%) | 44 (43.1%) | <0.001 |
| Follow-up period (days) | 1456 ± 648 | 1386 ± 685 | 0.30 |
ESRD: end-stage renal disease, Tac: tacrolimus, MMF: mycophenolate mofetil, PSL: prednisolone.